12.02.2025 / Deals & Cases

Deal: Wenger Vieli advised Akina on its CHF 2.8 Mio seed funding round

Wenger Vieli advised Akina, an innovative healthtech startup, on all legal aspects of its recent CHF 2.8 million seed funding round. The investment was led by Freigeist Capital and will enable Akina to further develop its AI-driven physiotherapy platform for home use.

Founded in 2021 as a spin-off from ETH Zurich and the ETH AI Center by Florian Haufe (CEO) and Michele Xiloyannis (CTO), Akina Health has developed AI software certified as a medical device that supports patients undergoing physiotherapy at home. The certified medical product "Akina Cloud" enables a personalized hybrid treatment approach, combining the flexibility of digitally supported home therapy with in-person appointments with physiotherapists. The system uses machine learning and camera-based motion analysis to guide patients with musculoskeletal conditions through therapeutic exercises and provides real-time feedback as well as automated progress reports and monitoring tools for healthcare professionals.

Akina is currently focused on treating musculoskeletal disorders such as back and joint pain, which are among the most common and costly physical complaints globally. By combining in-clinic treatments with digitally guided home therapy, Akina delivers significantly better and more sustainable treatment outcomes.

The funding round was led by Freigeist Capital, a venture capital firm specializing in technology- and design-driven startups. Additional contributions came from FAIR VC, Dr. Sattler Capital, Kickfund, and prominent Swiss healthcare experts. The funds will enable Akina to expand access to effective movement therapy, advance AI technology, and prepare for European expansion.

The team was led by Michael Baier (Partner, Corporate/M&A) and included Dominique Mattmann (Senior Associate, Corporate/M&A) and Michèle Joho (Senior Associate, Corporate/M&A).